Dr Reddy's Q2 profit falls 36%, plans semaglutide relaunch in November

What happened

Dr Reddy's Laboratories reported a 36% year-on-year fall in profit to Rs.925 crore and a 1.5% decline in consolidated revenue to Rs.8,671 crore for the September quarter, mainly due to lower North America sales of blood cancer drug lenalidomide, and it plans a semaglutide relaunch in November.

Confirmed

Global impact / market context

The profit drop shows how much Dr Reddy's results depend on one drug, lenalidomide, which means a single product loss can outweigh double-digit growth in the base business, emerging markets and India, pressuring earnings and cash available even as the company prepares a semaglutide relaunch.

Analyst inference

North America, the largest geography at 29% of revenue, fell 23% to Rs.2,489 crore, while emerging markets grew 24% and India rose 17%. This mix shift means investors will weigh whether new launches and the semaglutide relaunch can offset the lenalidomide gap and support the 20.6% Ebitda margin, which is operating profit as a share of sales.

Analyst inference

What to watch

1. Dr Reddy's said the base business, excluding lenalidomide in North America, kept delivering double-digit growth across businesses apart from Europe and the API business, and it ended the quarter with a net cash surplus of Rs.2,502 crore. Confirmed
2. The company plans to relaunch semaglutide in November; watch whether that launch adds revenue and how much it costs to market and supply, since spending on a launch is capital spending that can affect near-term profit. Proposed
3. Watch whether North America's 23% revenue decline narrows as new products and volume expansion offset the lenalidomide loss, and whether emerging markets and India keep growing fast enough to protect overall revenue and the 20.6% Ebitda margin. Analyst inference

Evidence

• Original source link unavailable